Childhood myelodysplasia.
The clinical data and hematological features of 29 children, under the age of 12 years, with primary myelodysplasia are presented. The diagnosis was made using the FAB (French-American-British) Cooperative Group criteria. There were 24 males and 5 females aged 4 months to 12 years (median 2.5 years) with marked male preponderance. Childhood myelodysplasia constituted 16% of all hematological malignancies and 36.7% of acute myeloid leukemias. The median duration of symptoms prior to diagnosis was 3 months. There were 15 cases of refractory anemia, one of refractory anemia with excess blasts, 3 of refractory anemia with excess blasts in transformation and 10 cases of chronic myelomonocytic leukemia. Five patients evolved to acute myeloid and 4 to acute lymphatic leukemia. The median duration of preleukemic phase in these patients was 7 months (range 4-29 months). The overall mean survival was short (5-9 months) in all the subgroups. Besides supportive therapy in most patients, two patients were treated with etoposide, one with alfa interferon 2b and one with high dose methylprednisolone. Our results show that myelodysplasia is not infrequent in children. The disease has an aggressive clinical course and may evolve into acute leukemia.
Agarwal
B R
BR
Department of Pediatric Hematology and Oncology, B.J. Wadia Hospital for Children, Parel, Bombay.
Currimbhoy
Z E
ZE
D002648:Child; D002675:Child, Preschool; D003906:Developing Countries; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D007223:Infant; D007938:Leukemia / Q000175:diagnosis / Q000401:mortality; D008297:Male; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000401:mortality; D011289:Preleukemia / Q000175:diagnosis / Q000401:mortality; D015996:Survival Rate